Biogen New Alzheimer Drug, Finally The Answer or A Bust?

Biogen is now reversing itself and declaring success for it’s current in-testing Alzheimer’s drug, BAN2401. This is the same drug that failed last year when compared against the placebo over a 12 months testing period. Biogen’s announcement last week is based on 18 months of testing data from the Phase 2 trial. The highest dosage…

Read More